US 11,925,336 B2
Guidewireless transseptal delivery system and method
Richard S Stack, Durham, NC (US); William L Athas, Durham, NC (US); and Kevin W Johnson, Durham, NC (US)
Assigned to Synecor LLC, Durham, NC (US)
Filed by Synecor LLC, Durham, NC (US)
Filed on Mar. 1, 2021, as Appl. No. 17/188,936.
Application 17/188,936 is a continuation of application No. 16/396,677, filed on Apr. 27, 2019, granted, now 10,959,713.
Application 16/396,677 is a continuation of application No. PCT/US2017/062913, filed on Nov. 22, 2017.
Claims priority of provisional application 62/473,495, filed on Mar. 20, 2017.
Claims priority of provisional application 62/461,788, filed on Feb. 22, 2017.
Claims priority of provisional application 62/443,492, filed on Jan. 6, 2017.
Claims priority of provisional application 62/425,584, filed on Nov. 22, 2016.
Prior Publication US 2021/0177389 A1, Jun. 17, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 17/00 (2006.01); A61M 25/00 (2006.01); A61M 25/01 (2006.01); A61M 25/10 (2013.01)
CPC A61B 17/00234 (2013.01) [A61M 25/0147 (2013.01); A61M 25/10 (2013.01); A61B 2017/00243 (2013.01); A61B 2017/00323 (2013.01); A61M 2025/0057 (2013.01); A61M 2025/1079 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method of delivering a therapeutic device to a target treatment site at a valve annulus in a heart of a patient, comprising the steps of:
(a) percutaneously introducing a cable into a vasculature of a patient and positioning the cable to run from a femoral vein, through the heart via a transseptal puncture, and to a femoral artery, such that a first end of the cable is exposed from the femoral vein and a second end, opposite the first end, of the cable is exposed from the femoral artery;
(b) at the femoral artery, securing the therapeutic device to the cable, the therapeutic device comprising a heart valve delivery device carrying a replacement valve;
(c) providing a left ventricle redirector (LVR) having a tubular lumen, advancing a distal end of the lumen over the cable at the femoral vein and advancing the LVR to the left ventricle;
(d) pulling the cable at the femoral vein while pushing the therapeutic device at the femoral artery to advance the therapeutic device to the target treatment site;
(e) during step (d), actively steering the distal end of the LVR, said steering modifying an orientation of a distal nose of the therapeutic device; and
(f) deploying the replacement valve at the valve annulus.